There are 2789 resources available
1363TiP - A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK+ advanced/metastatic NSCLC
Presenter: Ben Solomon
Session: ePoster Display
1474P - Patient characteristics and treatment patterns in patients with metastatic pancreatic cancer by BRCA/ATM status in the PRIOR-2 study
Presenter: Maria Sierra
Session: ePoster Display
1365TiP - A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy
Presenter: Sun Min Lim
Session: ePoster Display
1366TiP - Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
Presenter: Yi-Long Wu
Session: ePoster Display
1367TiP - IMPRINTER: An open label, multi-center, dose escalation/expansion, phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer
Presenter: Rita Laeufle
Session: ePoster Display
1543P - Gemcitabine in classic Kaposi’s sarcoma: A pilot study
Presenter: Giuseppe Badalamenti
Session: ePoster Display
1544P - Soft tissue sarcoma (STS) incidences and clinical characteristics are significantly different between different geographic and ethnic populations
Presenter: Tom Wei-Wu Chen
Session: ePoster Display
1545P - Initial presentation of sarcomas in adult patients from private and public health insurance systems in Brazil: A single center analysis
Presenter: Celso Filho
Session: ePoster Display
1375P - SHR-1701, a novel bifunctional anti-PD-L1/TGF-βRII agent, for pretreated recurrent/refractory (r/r) gastric cancer (GC): Data from a first-in-human phase I study
Presenter: Dan Liu
Session: ePoster Display